Start here if you're new
what it is
Axcelis sells the machines chipmakers use to shoot ions into silicon, then gets paid again to keep those machines running.
how it gets paid
Last year Axcelis Tech made $839M in revenue. systems - asia pacific was the main engine at $451.5M, or 54% of sales.
why growth slowed
Revenue fell 17.6% in 2025. FY2025 non-GAAP diluted EPS $4.88 and GAAP diluted EPS $3.80—both below FY2024 levels in the same filing tables.
what just happened
Q4’25: GAAP diluted EPS $1.10; non-GAAP diluted EPS $1.49—consensus “beat” language usually refers to the non-GAAP line.
At a glance
B+ balance sheet — decent shape, but not bulletproof
45/100 earnings predictability — expect surprises
~17× trailing on non-GAAP EPS ($4.88 FY2025)
10.0% return on capital — nothing to write home about
$4.00 fy2027 eps est
xvary composite: 55/100 — below average
What they do
Axcelis sells the machines chipmakers use to shoot ions into silicon, then gets paid again to keep those machines running.
Axcelis sells the machine first and the dependency second. Systems were 69% of 2025 sales, but aftermarket was 31%, which means once its Purion tools are on your fab floor, your spare parts and service budget starts following them. Customer concentration is brutal at 70% of sales from the top 10 customers in 2025, but that also tells you these are large fabs making repeat, high-stakes tool choices.
How they make money
$839M
annual revenue · their business grew -17.6% last year
systems - asia pacific
$451.5M
17.6%
systems - europe
$86.8M
17.6%
systems - north america
$40.5M
17.6%
aftermarket - asia pacific
$202.9M
0.0%
aftermarket - europe and north america
$57.2M
0.0%
The products that matter
chip implantation equipment
Ion Implantation Systems
$579M · 69% of revenue
Systems revenue ~$579M (~69% of FY2025 sales) vs. aftermarket ~31%—total company revenue still fell 17.6% from 2024; do not assume systems dollars grew unless the segment table in filings says so.
core
largest end market
Asia Pacific Revenue Base
$654M · 78% of revenue
this is where most of the money comes from. when one region supplies 78% of sales, recovery there matters more than almost any slide deck promise.
concentration
secondary regional base
Europe Revenue Base
$126M · 15% of revenue
europe accounts for $126M of revenue. useful diversification, but not enough to offset weakness if asia slows.
secondary
Key numbers
~17×
trailing P/E (non-GAAP)
~$84.06 ÷ $4.88 FY2025 non-GAAP diluted EPS—GAAP EPS was $3.80 (multiple ~22×).
~14.3%
GAAP net margin
$120.2M net income on $839.0M revenue ≈ 14.3¢ per sales dollar—still profitable in a down cycle, but not a 15% round number.
10.0%
return on capital
Return on capital means profit on the money tied up in the business. At 10.0%, this is solid, not elite.
$41M
long-term debt
Debt is only 2% of capital, so the balance sheet is not the problem here. Demand is.
Financial health
B+
strength
- balance sheet grade B+ — solid but not elite
- risk rank 3 — safer than 50% of stocks
- price stability 15 / 100
- long-term debt $41M (2% of capital)
- net profit margin ~14.3% GAAP FY2025 — $120.2M net income on $839.0M revenue
- return on equity 12% — $0.12 profit for every $1 investors have put in
B+ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in ACLS 3 years ago → it's now worth $6,490.
The index would have given you $14,540.
source: institutional data · total return
What just happened
beat estimates
Q4’25 non-GAAP diluted EPS $1.49 (GAAP $1.10) vs. revenue $238.3M—check your data feed for which EPS line matched “consensus.”
FY2025: revenue $839.0M (−17.6%); GAAP diluted EPS $3.80; non-GAAP diluted EPS $4.88. FY2024 was higher on both GAAP and non-GAAP lines—use Axcelis’s reconciliation for an exact prior-year match.
$839M
revenue
$1.49
Q4 non-GAAP EPS
44.1%
gross margin
the number that mattered
Semiconductor equipment is cyclical—quarterly beats on adjusted EPS do not cancel a full-year revenue down-cycle.
-
the completion of this transaction remains subject to other customary closing conditions.this includes the final pending regulatory approval from the state administration for market regulation of china. if the deal goes through, the combined business would assume a new name, ticker symbol, and brand following closing.
-
axcelis and veeco continue to expect that the merger will be completed in the second half of 2026.
-
axcelis’ top line is currently under stress, but should turn the corner next year.
-
in 2025, revenues fell 18% because of a drop in system sales.on a brighter note, axcelis is seeing signs that customers in china are starting to expand their silicon carbide device capacity. management believes that growing demand for ai-powered devices will benefit the business in the long run. also, leadership has announced the launch of purion h6, a next-generation high current ion implanter. this product is designed for semiconductor manufacturing applications across the logic, advanced memory, image sensor, and mature technology market segments.
-
in 2026, we expect the top line to remain flat.
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is china approval delaying or blocking the veeco merger.
med
veeco deal does not close on schedule
management expects closing in the second half of 2026, but the deal still needs final approval from china and other customary conditions. that keeps event risk alive for a long time.
if the deal breaks, the market has a clear fallback reference point: ACLS already traded as low as $40 over the last 52 weeks.
med
asia pacific concentration cuts both ways
asia pacific generates $654M, or 78% of revenue. that concentration helps when demand is strong and hurts when customers pause spending or approvals get messy.
one region drives most of the business, so you are not getting much geographic diversification for free.
med
systems weakness lasts longer than the street expects
systems account for $579M, or 69% of revenue. 2025 revenue fell 18% because system sales dropped, and 2026 revenue is only estimated at $840M. that is stabilization, not a rebound.
if system demand stays weak, the low multiple will look less like a bargain and more like the correct price for a stalled cycle.
between 78% asia exposure, 69% systems concentration, and a merger still waiting on china, this is a stock where one approval and one demand cycle can move the whole story.
source: institutional data · regulatory filings · risk analysis
Pay attention to
risk
china merger approval
the veeco deal is still waiting on final approval from china, and management is guiding to a second-half 2026 close.
metric
systems revenue
systems are $579M of revenue. if that line keeps shrinking, the recovery case gets thinner fast.
trend
china silicon carbide capacity
management says customers in china are starting to expand silicon carbide device capacity again. you want to see that move from commentary to revenue.
calendar
2026 flat revenue setup
the street is modeling roughly $840M of revenue for 2026. that makes each quarter a simple test: flat is acceptable, another leg down is not.
Analyst rankings
risk profile
average
stability score 3 means this sits near the middle of the pack. in human-speak, analysts do not see a bunker stock or a disaster candidate.
earnings predictability
45 / 100
predictability at 45/100 means future quarters are harder to model than average. translation: expect the cycle to make the numbers lumpy.
source: institutional data
Institutional activity
institutions have been net buying for 3 consecutive quarters — 132 buyers vs. 126 sellers in 4q2025. total institutional holdings: 31.5M shares. net buying for 3 quarters.
source: institutional data
Price targets
3-5 year target range
$52
$142
$84
current price
$97
target midpoint · +15% from current · 3-5yr high: $115 (+35% · 8% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive